The integrated agency's pharmaceutical business now brings in half its billings.
Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend
Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment
He didn't want to just invest in a winning horse—he wanted to help groom it
The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.
Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.
UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth
Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.
The deal is expected to complement the company's digital health platform.
Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition